-
Innovation Ranking
NewInnovation Ranking – Element Solutions Inc
Element Solutions Inc (Element Solutions) is a diversified producer of high-technology specialty chemical products. The company's products include water-based hydraulic control fluids, surface and coating materials, photopolymers, and crop protection products which comprise fungicides, herbicides and insecticides. It offers its chemicals and processes to various industries which include agriculture, automotive, electronics, graphic arts, metals, plastic plating, animal health and offshore oil and gas production and drilling. Element Solutions also offers technical services. It markets its products under various brands including...
-
Company Insights
NewDecoding Procter & Gamble’s YouTube Advertisement Strategy in Q1 2024
The report on Procter & Gamble's advertising strategies on YouTube during the first quarter of 2024, focus on key products such as Fairy Maxx and Puffs Plus. It analyzes the core themes, messaging strategies, and product benefits portrayed in these advertisements, highlighting elements such as Convenience, Efforless Cleaning, Comfort and Relief benefits. Moreover, the report examines the overarching themes of comfort, quality and sustainability infused into these campaigns. By synthesizing these insights, the report aims to provide a nuanced understanding...
-
Company Insights
NewDecoding Mastercard’s YouTube Advertising Strategy in Q1 2024​
The report on Mastercard's advertising strategies on YouTube during the first quarter of 2024, focuses on key products and services such as March Mastercard, Mastercard credit Card Services and Mastercard Secure Card. It analyzes the core themes, messaging strategies, and product benefits portrayed in these advertisements, highlighting elements such as Security Enhancements, Efficient Transactions and Cutting-Edge Technologies. Moreover, the report examines the overarching themes of innovation, convenience and effeciency into these campaigns. By synthesizing these insights, the report aims to...
-
Company Insights
NewDecoding Coca Cola’s YouTube Advertising Strategy in Q1 2024​
The report on Coca-Cola's advertising strategies on YouTube during the first quarter of 2024, focus on key products such as Coca-Cola Real Magic, Coca-Cola Zero Sugar Sommelier, and New Coca-Cola Spiced. It analyzes the core themes, messaging strategies, and product benefits portrayed in these advertisements, highlighting elements such as Cost Saving, Flavor Diversity, and Refreshing Tastes. Moreover, the report examines the overarching themes of Fun, Casual Conversations, and Energy infused into these campaigns. By synthesizing these insights, the report aims...
-
Company Insights
NewDecoding American Express’s YouTube Advertising Strategy in Q1 2024
The report on American Express's advertising strategies on YouTube during the first quarter of 2024, focus on key products such as Amex Platinum Card and Amex Delta SkyMiles Platinum Card. It analyzes the core themes, messaging strategies, and product benefits portrayed in these advertisements, highlighting elements such as Exclusive Dining Experiences, Luxurious Travel Experiences and Complimentary Breakfast Benefits. Moreover, the report examines the overarching themes of Luxury, Convenience and Adventure infused into these campaigns. By synthesizing these insights, the report...
-
Product Insights
Likelihood of Approval Analysis for Allergies
Overview How likely is it that the drugs in Allergies will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Allergies Overview Allergies result from an immune system reaction to substances that typically...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – LY-3885125 in Dyslipidemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - LY-3885125 in Dyslipidemia report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. LY-3885125 in Dyslipidemia Drug Details: LY-3885125 is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CAN-3110 in High-Grade Glioma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CAN-3110 in High-Grade Glioma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CAN-3110 in High-Grade Glioma Drug Details: RQNestin-34.5v.2 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – LY-3885125 in Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - LY-3885125 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. LY-3885125 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Drug Details: LY-3885125...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CAN-3110 in Recurrent Glioblastoma Multiforme (GBM)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CAN-3110 in Recurrent Glioblastoma Multiforme (GBM) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CAN-3110 in Recurrent Glioblastoma Multiforme (GBM) Drug Details: RQNestin-34.5v.2 is...